"Anthracyclines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
Descriptor ID |
D018943
|
MeSH Number(s) |
D02.455.426.559.847.562.050 D04.615.562.050 D09.408.051.059
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Anthracyclines".
Below are MeSH descriptors whose meaning is more specific than "Anthracyclines".
This graph shows the total number of publications written about "Anthracyclines" by people in this website by year, and whether "Anthracyclines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 2 | 2 |
1997 | 1 | 1 | 2 |
1999 | 1 | 0 | 1 |
2001 | 2 | 0 | 2 |
2002 | 0 | 1 | 1 |
2003 | 2 | 0 | 2 |
2004 | 5 | 5 | 10 |
2005 | 4 | 5 | 9 |
2006 | 6 | 4 | 10 |
2007 | 5 | 4 | 9 |
2008 | 3 | 6 | 9 |
2009 | 2 | 7 | 9 |
2010 | 4 | 7 | 11 |
2011 | 4 | 3 | 7 |
2012 | 6 | 3 | 9 |
2013 | 3 | 5 | 8 |
2014 | 5 | 0 | 5 |
2015 | 3 | 3 | 6 |
2016 | 6 | 3 | 9 |
2017 | 5 | 7 | 12 |
2018 | 2 | 2 | 4 |
2019 | 2 | 3 | 5 |
2020 | 5 | 1 | 6 |
2021 | 3 | 7 | 10 |
2022 | 0 | 3 | 3 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anthracyclines" by people in Profiles.
-
Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report. Leuk Lymphoma. 2024 Jan; 65(1):62-68.
-
Early skeletal muscle loss in adolescent and young adult cancer patients treated with anthracycline chemotherapy. Cancer Med. 2023 11; 12(22):20798-20809.
-
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 10 03; 28(10):845-855.
-
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.
-
Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. Int J Biol Sci. 2023; 19(14):4644-4656.
-
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
-
Myxoid Liposarcomas: Systemic Treatment Options. Curr Treat Options Oncol. 2023 04; 24(4):274-291.
-
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle? Eur J Cancer. 2023 05; 185:94-104.
-
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023 04 01; 41(10):1841-1848.
-
Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic?Cancer Therapy: 3-Year Results of the SUCCOUR Trial. JACC Cardiovasc Imaging. 2023 03; 16(3):269-278.